Chengdu Kanghua Biological Products Co., Ltd.
SZSE:300841.SZ
64.68 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,431.877 | 1,577.395 | 1,446.725 | 1,292.448 | 1,038.636 | 554.637 | 559.468 | 261.93 | 92.916 | 71.069 |
| Cost of Revenue
| 83.007 | 103.779 | 93.135 | 83.75 | 62.844 | 32.349 | 31.091 | 27.617 | 8.627 | 11.103 |
| Gross Profit
| 1,348.869 | 1,473.616 | 1,353.59 | 1,208.698 | 975.792 | 522.287 | 528.376 | 234.314 | 84.29 | 59.967 |
| Gross Profit Ratio
| 0.942 | 0.934 | 0.936 | 0.935 | 0.939 | 0.942 | 0.944 | 0.895 | 0.907 | 0.844 |
| Reseach & Development Expenses
| 132.051 | 253.026 | 179.941 | 78.875 | 58.254 | 22.786 | 18.923 | 4.274 | 6.355 | 5.009 |
| General & Administrative Expenses
| 34.439 | 29.755 | 24.912 | 30.95 | 33.27 | 29.231 | 29.176 | 4.078 | 19.528 | 14.72 |
| Selling & Marketing Expenses
| 504.083 | 448.532 | 428.119 | 412.07 | 371.045 | 217.038 | 249.019 | 110.803 | 29.977 | 12.495 |
| SG&A
| 538.522 | 610.867 | 453.031 | 443.02 | 404.315 | 246.269 | 278.195 | 114.881 | 49.505 | 27.215 |
| Other Expenses
| 211.012 | 33.111 | 50.185 | 269.145 | -1.121 | -0.071 | -0.205 | -0.03 | 0.385 | 1.434 |
| Operating Expenses
| 881.586 | 897.004 | 688.121 | 567.508 | 499.968 | 291.987 | 313.851 | 131.874 | 56.583 | 32.49 |
| Operating Income
| 467.284 | 576.612 | 685.502 | 915.758 | 485.06 | 223.404 | 189.629 | 90.905 | 6.734 | 13.494 |
| Operating Income Ratio
| 0.326 | 0.366 | 0.474 | 0.709 | 0.467 | 0.403 | 0.339 | 0.347 | 0.072 | 0.19 |
| Total Other Income Expenses Net
| -0.26 | -2.619 | -1.709 | -0.179 | -1.121 | -0.071 | -0.205 | -0.03 | 0.385 | 1.434 |
| Income Before Tax
| 467.023 | 573.994 | 683.793 | 915.579 | 483.938 | 223.333 | 189.424 | 90.875 | 7.119 | 14.928 |
| Income Before Tax Ratio
| 0.326 | 0.364 | 0.473 | 0.708 | 0.466 | 0.403 | 0.339 | 0.347 | 0.077 | 0.21 |
| Income Tax Expense
| 68.371 | 64.778 | 85.727 | 86.101 | 75.892 | 36.646 | 35.284 | 16.418 | 0.461 | 3.227 |
| Net Income
| 398.652 | 509.216 | 598.066 | 829.478 | 408.046 | 186.687 | 154.14 | 74.458 | 6.658 | 11.702 |
| Net Income Ratio
| 0.278 | 0.323 | 0.413 | 0.642 | 0.393 | 0.337 | 0.276 | 0.284 | 0.072 | 0.165 |
| EPS
| 3.03 | 3.81 | 4.47 | 6.15 | 3.02 | 1.38 | 1.54 | 0.55 | 0.049 | 0.087 |
| EPS Diluted
| 3.03 | 3.81 | 4.46 | 6.14 | 3.02 | 1.38 | 1.54 | 0.55 | 0.049 | 0.087 |
| EBITDA
| 537.631 | 630.264 | 728.084 | 937.527 | 496.429 | 233.869 | 199.221 | 105.733 | 26.376 | 34.756 |
| EBITDA Ratio
| 0.375 | 0.4 | 0.503 | 0.725 | 0.478 | 0.422 | 0.356 | 0.404 | 0.284 | 0.489 |